Esperion Therapeutics
ESPR
#6359
Rank
A$1.17 B
Marketcap
A$4.93
Share price
-1.86%
Change (1 day)
69.51%
Change (1 year)

Earnings for Esperion Therapeutics (ESPR)

Earnings in 2025 (TTM): -A$43.8 Million

According to Esperion Therapeutics's latest financial reports the company's current earnings are A$0.30 Billion. In 2024 the company made an earning of A$10.75 Million, an increase over its 2023 earnings that were of -A$0.22 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Esperion Therapeutics from 2000 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -A$43.8 Million-507.32%
2024 A$10.75 M-104.99%
2023 -A$0.22 Billion-15.03%
2022 -A$0.26 Billion-20.61%
2021 -A$0.32 Billion84.28%
2020 -A$0.18 Billion35.75%
2019 -A$0.13 Billion-55.71%
2018 -A$0.29 Billion19.57%
2017 -A$0.25 Billion125.39%
2016 -A$0.11 Billion51.43%
2015 -A$70.58 Million36.45%
2014 -A$51.73 Million43.55%
2013 -A$36.03 Million145.26%
2012 -A$14.7 Million
2002 -A$41.89 Million-7.81%
2001 -A$45.43 Million15.03%
2000 -A$39.5 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
A$16.97 B-43,290.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
A$7.37 B-18,849.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Ultragenyx Pharmaceutical
RARE
-A$0.75 Billion 1,790.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Lexicon Pharmaceuticals
LXRX
-A$98.24 Million 149.91%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
A$7.13 M-118.16%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
A$0.97 B-2,575.39%๐Ÿ‡บ๐Ÿ‡ธ USA